Astrazeneca (AZN) Retained Earnings (2009 - 2026)

Astrazeneca has reported Retained Earnings for 18 years, with the latest figure at $12.6 billion in Q2 2026.

• On a quarterly basis, Retained Earnings rose 79.3% year-over-year to $12.6 billion in Q2 2026; TTM through Jun 2026 was $12.6 billion, a 79.3% increase from a year earlier, with the FY2025 full-year figure at $11.0 billion, up 247.22% from the prior year.
• Retained Earnings was $12.6 billion for Q2 2026 at Astrazeneca, up from $9.7 billion in the prior quarter.
• The five-year high for Retained Earnings was $12.6 billion in Q2 2026, with the low at -$2.5 billion in Q3 2022.
• Average Retained Earnings over 5 years is $2.9 billion, with a median of $1.7 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 212.32% in 2022, then jumped 1686.79% in 2025.
• Over 5 years, Retained Earnings stood at -$574.0 million in 2022, then surged by 361.67% to $1.5 billion in 2023, then jumped by 110.39% to $3.2 billion in 2024, then jumped by 247.22% to $11.0 billion in 2025, then rose by 14.76% to $12.6 billion in 2026.
• The last three Retained Earnings figures came in at $12.6 billion (Q2 2026), $9.7 billion (Q1 2026), and $11.0 billion (Q4 2025), per Business Quant data.